Prospective, Single-arm Study to Assess the Safety and Performance of the Omega™ Left Atrial Appendage (LAA) Occluder in Patients With Non-Valvular Atrial Fibrillation and High Bleeding Risk

Vascular Innovations Co. Ltd.2 sites in 2 countries20 target enrollmentJune 1, 2019

ConditionsAtrial Fibrillation

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Atrial Fibrillation
Sponsor: Vascular Innovations Co. Ltd.
Enrollment: 20
Locations: 2
Primary Endpoint: LAA closure
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

Atrial fibrillation is associated with increased risk of stroke mostly because of clot formation in the left atrial appendage, a small alcove in the left atrium heart chamber. Plugging this appendage with an implantable plug type device, which is placed via a catheter painlessly in the femoral vein, has been proven to be a reliable alternative to the standard anti-clotting medication in a number of recent international trials. The Omega device is a new design of such a plug, made from biocompatible and compressible nitinol and fabric.

Up to 195 patients will be enrolled in Europe, assuming that enrolment will stop once the Omega™ device has been successfully implanted in 150 evaluable patients.

The primary performance endpoint of the study is LAA closure (defined as complete seal or efficient seal with a peri-device leak ≤ 5 mm) at 60 days (+/- 15 days) visit documented by transoesophageal echocardiogram (TEE/TOE) with colour flow Doppler.

Detailed Description

This is a single arm study to assess the safety and performance of the Omega™ Left Atrial Appendage (LAA) Occluder in patients with Non-valvular atrial fibrillation (NVAF) and high bleeding risk. The study will be conducted in accordance with the ISO standard ISO 14155 (Clinical investigation of medical devices for human subjects - Good clinical practice) and other legal requirements as applicable. The primary performance endpoint of the study is LAA closure (defined as complete seal or efficient seal with a peri-device leak ≤ 5 mm) at 60 days (+/- 15 days) visit documented by transoesophageal echocardiogram (TEE/TOE) with colour flow Doppler. The primary safety endpoint of the study is device-related complications (serious adverse events \[SAEs\]) through 60 days (+/- 15 days) post-procedural. Following consent a number of assessments will be undertaken prior to the procedure to ensure the study eligibility criteria are met. These assessments include; medical history, physical exams, ECG, blood tests, transthoracic echocardiogram, transesophageal echocardiogram and cardiac CT. The implant procedure will usually be performed under general anaesthetic. A thin catheter is inserted in the femoral vein in the right groin area and advanced under X-Ray guidance to the right atrium, then a very small needle is used to cross through to the left atrium to allow the delivery catheter to place the Omega in the Appendage, guided by both X-Ray and transesophageal echo. A medication regimen for endocarditis prophylaxis anticoagulation is recommended post procedure. Following discharge, patients will be seen again at 60 days, 6 months and 12 months to collect data for the primary performance endpoint (by TTE or TEE) and safety endpoints (mRS, stroke/TIA assessments, and ECG). An interim analysis is planned following the collection of 60 day data for the first 10 patients implanted with the device. An additional interim analysis will be performed following the collection of 60 days (+/- 15 days) data for the first 50 patients implanted with the device. Final analysis will be performed once all 150 subjects have been implanted with the device and completed the study to further document and confirm the safety and effectiveness of the device.

Registry

clinicaltrials.gov

Start Date

June 1, 2019

End Date

March 31, 2020

Last Updated

5 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Vascular Innovations Co. Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•60 years of age or older
•Documented paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF)
•At increased risk of stroke or systemic embolism defined as CHADS2 score \> 2 or a CHA2DS2-VASc score \> 3
•Deemed, by investigator, to be unsuitable or contraindicated for long term oral anticoagulation therapy due to high bleeding risk
•To have suitable anatomy for percutaneous LAA occlusion procedure with a single Omega™ device based on CT scan evaluation
•Able and willing to comply with the required medication regimen post-device implant
•Able to understand and willing to provide written informed consent to participate in the study
•Able to and willing to return for required follow-up visits and examinations.
•Exclusion criteria:
•Requires long-term oral anticoagulation therapy for any indication other than atrial fibrillation

Exclusion Criteria

•Intracardiac thrombus - including LAA - visualized by echocardiographic imaging
•Existing circumferential pericardial effusion \>2mm
•Significant mitral valve stenosis (i.e. mitral valve area \<1.5 cm2)
•High risk patent foramen ovale (PFO), defined as an atrial septal aneurysm (atrial septal excursion \>15mm; excursion defined as maximal protrusion of the ASA beyond the plane of the atrial septum during cardiac cycle) or large shunt (substantial passage of bubbles, i.e. \>25, within 3 cardiac cycles from appearing in the right atrium)
•Complex atheroma with mobile plaque of the descending aorta and/or aortic arch
•Cardiac tumour
•LAA anatomy cannot accommodate an Omega™ device (as per IFU)
•Placement of the device would interfere with any intracardiac or intravascular structure.